Repository logo

  • Help
  • Log In(current)
    1. Home
    2. NT Health Research
    3. Research and Conference Publications
    4. A phase II trial of palbociclib and avelumab in advanced solid tumours with CDK4/6 pathway alterations
    Details
    Title

    A phase II trial of palbociclib and avelumab in advanced solid tumours with CDK4/6 pathway alterations

    Conference Name
    ESMO Congress 2025
    Conference Start Date
    2025-10-17
    Conference End Date
    2025-10-21
    Conference Location
    Berlin, Germany
    Author(s)
    Kansara, M.
    Thavaneswaran, S.
    Lin, F.P.
    Kok, P-S.
    Grady, J.
    Thomas, H.
    Corpuz, T.
    Mundra, P.
    Lu, J.
    Ballinger, M.
    Desai, J.
    Harrup, R.A.
    Craft, P.
    Charakidis, Michail
    O'Byrne, K.J.
    Selva-Nayagam, S.
    Millward, M.
    Grimison, P.
    Simes, J.
    Thomas, D.
    Abstract
    Background: Preclinical data demonstrate synergy between CDK4/6 inhibition and PD-L1 blockade, enhancing immune response and tumour control. This study evaluated palbociclib priming followed by the addition of avelumab in advanced solid tumours with cell cycle pathway alterations.
    Methods: This single-arm phase 2 trial (ACTRN12620000568910) enrolled patients(pts) (≥18 years) with advanced cancers, ECOG 0—2. Molecular eligibility required either a CDK4/CCND1—3 gain-of-function (GoF) or CDKN2A loss-of-function (LoF)mutation. Pts received palbociclib (125 mg PO, 21/28-day cycle) alone for the first cycle, followed by palbociclib and avelumab (10 mg/kg IV q2w) until progression or unacceptable toxicity. A tumour biopsy was performed after cycle 1. The primary endpoint was 6-month PFS (PFS6) on combination therapy. Secondary endpoints included overall PFS, OS, objective tumour response (OTR), time to progression ratio TTPr (TTP2:TTP1), safety and QoL). TTPr >1.3 indicated clinical benefit. Correlative
    analyses evaluated immune activation.
    Results: A total of 64 pts were enrolled between March 2021 and September 2022 (32 in each of the GoF and LoF cohorts). In the GoF cohort the most common cancers were sarcomas (n=18), while pancreas cancers predominated in the LoF cohort (n=10). No confirmed OTR were observed. PFS6 was 40% (11/26; 95% CI: 0.23 to
    0.57) in GoF cohort, including pts with liposarcoma (n=5), and one of each myofibroblastic, ovarian, uterine, small intestine, lung, and liver cancers. In the LoF cohort, PFS6 was 16% (4/24; 95% CI: 0.05 to 0.33), including pts with chordoma, leiomyo sarcoma, GIST, and acinar cell carcinoma. A rTTP >1.3 was observed in 50% (15/30) of GoF and 23%(6/26) of the LoF pts. Median OS was 12.7 mo for GoF and 5.6 mo for the LoF cohort. No new safety signals were identified. Correlative studies revealed immune activation markers in both blood and in tumour following cycle 1 which
    were associated with clinical benefit.
    Conclusions: While no objective responses were observed, the GoF cohort showed a favourable TTPr and PFS6 in rare cancers. These results support continued investigation of CDK4/6 and PD-L1 blockade in genomically selected patients.
    Publication information
    Ann Oncol. September 2025Annals of Oncology 36:S922-S923 DOI:10.1016/j.annonc.2025.08.2175
    Date Issued
    2025-09-01
    Type
    Conference abstract
    Journal Title
    Annals of oncology
    Permanent link to this record
    https://hdl.handle.net/10137/14927
    Link to related resource
    Click for abstract
    Owning collection
    Research and Conference Publications

    NT Health Library Services acknowledges the Traditional Custodians of Country throughout the Northern Territory and recognises their continuing cultural and spiritual connections to the lands, waters, and communities. We pay our respects to elders past, present and emerging, and extend that respect to all Aboriginal and Torres Strait Islander people across the Northern Territory and beyond, many of whom are represented in our collections.

    © 2025 Northern Territory Government of Australia